Form 4: AN2 Therapeutics Director Patricia A. Martin Granted Stock Options

Patricia A. Martin, a director of AN2 Therapeutics, was granted stock options to purchase 64,503 shares of common stock on June 19, 2024.

Summary

• Patricia A. Martin, a director of AN2 Therapeutics, Inc., filed a Form 4 with the SEC on June 21, 2024.
• The form reports a transaction that occurred on June 19, 2024, where Ms. Martin was granted stock options to purchase 64,503 shares of AN2 Therapeutics common stock.
• The exercise price of the options is $2.00 per share.
• The options vest on the earlier of (a) the one-year anniversary of June 19, 2024, or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to continuous service.
• The options expire on June 18, 2034.
• Ms. Martin also has a Power of Attorney agreement, effective December 13, 2023, allowing certain individuals to execute SEC filings on her behalf.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a common practice and generally viewed as a positive sign of aligning director interests with shareholders. There are no negative aspects presented in the document.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service by the director.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of compensation for directors and executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to incentivize directors and management.
• The vesting schedule of one year is fairly typical.
• Comparing the size of the grant (64,503 shares) to similar companies would require analyzing their compensation structures and outstanding share counts.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's success.
• The director is incentivized to contribute to the company's growth to increase the value of the options.

Key Dates